Pulmonary large cell neuroendocrine carcinoma
MONDO:0003960A large cell neuroendocrine carcinoma that involves the lung(s).
Also known as: LCNEC of the lung, large cell lung carcinoma with neuroendocrine differentiation, large cell lung neuroendocrine carcinoma, large cell neuroendocrine carcinoma of lung, large cell neuroendocrine carcinoma of the lung, lung large cell neuroendocrine carcinoma, pulmonary large cell neuroendocrine carcinoma
2853 clinical trials for this condition and its sub-types, 20 tagged with Pulmonary large cell neuroendocrine carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pulmonary large cell neuroendocrine carcinoma
-
New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial
Disease control OngoingThis early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
New drug combo targets rare, aggressive cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental combo aims to boost immune attack on tough lung cancers
Disease control OngoingThis early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Radioactive drug targets tough lung cancers in early trial
Disease control OngoingThis early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine lung cancer that has spread and was previously treated with platinum chemotherapy. The main goals are to check safety, find the best dose, and see…
Phase 1 • Sponsor: Abdera Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy plus chemo shows promise for rare lung cancer
Disease control OngoingThis phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) can help people with advanced large-cell neuroendocrine lung cancer live longer. About 67 participants who have not had prior systemic treatment wil…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take aim at tough lung cancer
Disease control OngoingThis early-phase study tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack DLL3, a protein found on certain lung cancer cells. The study includes about 41 adults with advanced small cell lung ca…
Phase 1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC